Sir, Reply to Ramamurthi and Rahman
The authors incorrectly cite Ian Mackie's paper (reference 41). Mackie did not advocate the induction of ptosis with botulinum toxin for the treatment of recurrent corneal erosions.
His method was to reduce the action of the orbital part of the orbicularis muscle by injecting it with botulinum toxin.
Thirty-five years ago, Mackie had shown that contraction of the orbital portion of the orbicularis muscle stopped Bell's phenomenon. 1 Normal blinking involves only the palpebral portion of the orbicularis muscle and is accompanied by Bell's phenomenon. He presumed that orbital orbicularis action prevented Bell's phenomenon during rapid eye movements in sleep and induced corneal erosion.
Using a modification of Mackie's method, in which I inject into the upper eyelid Riolan's muscle, I have successfully treated eight cases of recalcitrant recurrent corneal epithelial erosions without noticeably altering the eyelid position. The intention is to reduce horizontal tension in the lid, on the basis that shearing between the lid and the ocular surface in combination with overnight reduction in tear secretion, and thus lubrication, is contributory.
I make two injections, each of 4 IU of Botox TM or 12 IU of Dysport TM , just above the upper-lid margin near the medial and lateral canthi (Figure 1 ). The choice of injection site was inspired by Mackie's paper on Riolan's muscle. Sir, Intravitreal triamcinolone and bevacizumab combination therapy for macular edema due to central retinal vein occlusion refractory to either treatment alone A review of the literature showed no published cases using a combination of intravitreal triamcinolone and anti-VEGF agents for macular edema due to central retinal vein occlusion (CRVO). We present a case refractory to each treatment modality separately but which responded to their combination.
Case report
A 70-year-old hypertensive gentleman, with CRVO in the left eye, presented with a CRVO in the right eye. On presentation, his vision was 20/70 in the right eye and 20/400 in the left. His vision remained stable in the left eye.
The right eye showed cystoid macular edema (CME) on optical coherence tomography (OCT). After discussion of the risks and benefits of off-label intravitreal bevacizumab, 1.25 mg (0.05 ml) intravitreal bevacizumab (Avastin, Genentech, San Francisco, CA, USA) was given. After three monthly injections, his vision improved to 20/40 with decreased CME (Figure 1 ). One month after the fourth bevacizumab injection, his vision deteriorated to 20/80 with increased CME. Intravitreal triamcinolone acetonide (Kenalog, 4 mg (0.1 cc) Bristol-Myers-Squibb, Peapack, NJ, USA) was given. One month later, his vision was 20/25 with CME resolution. His vision declined to 20/100 with recurrent CME 4 weeks later. After two more monthly bevacizumab injections, his vision continued to deteriorate to 20/150. At this time, another intravitreal triamcinolone was given, with further deterioration of his vision to 20/400 without change in the amount of CME (Figure 2 ).
One year after presentation, he was offered combination therapy with intravitreal triamcinolone and bevacizumab. An intravitreal triamcinolone injection (the third) followed 1 week later with intravitreal bevacizumab (the seventh) was given. The patient immediately noted a dramatic improvement in his vision. At the 1-month follow-up, his vision was 20/40, and there was resolution of fluid on OCT (Figure 3 ). Three months after the combination therapy, his CME recurred with resolution after a second combination treatment, and an improvement in vision from 20/70 to 20/40.
Comment
Intravitreal bevacizumab and triamcinolone are used off-label as treatment for CME due to CRVO. [1] [2] [3] [4] In this case, which became recalcitrant to monotherapy with intravitreal bevacizumab or triamcinolone, their Sir, Acute hydrops in a corneal graft for keratoconus
Case report
A 50-year-old gentleman presented to eye casualty with a 1 week history of reduced vision and headache above his left eye. He had a left corneal graft for keratoconus in 1988 and had not been seen by us since 1993 when his aided vision was 6/9 right 6/36 left.
On examination, his aided visual acuity was 6/12 right and hand movements left. On the right side, there was a mild keratoconus. On the left side there was severe oedema of the corneal graft and an obvious split in Descemet's membrane in the graft. The host cornea was unaffected (Figure 1) .
A diagnosis of hydrops affecting the corneal graft was performed. He was treated with intensive topical steroid as the differential diagnosis was of graft rejection. However, the steroid drops were quickly tailed down as they did not seem to improve the clinical course and we were confident with our diagnosis.
One month later, the hydrops had resolved leaving only minimal scarring and slightly increased graft thickness (Figure 2 ). His visual acuity was 6/12 right 1/36 left with glasses.
Comment
Keratoconus is a progressive, bilateral, non-inflammatory degenerative condition, leading to increasing irregular astigmatism. Keratoplasty is indicated when other treatment methods such as glasses, contact lenses, INTACS or DALK either fail or are not suitable. It has been shown that keratoconus can recur in a graft in 11.7% cases, with a mean time to recurrence of 17 years. 1 Hydrops is caused by a break in Descemet's membrane and is believed to occur in 2.6-2.8% cases with keratoconus. 2 The differential diagnosis for hydrops occurring within a graft includes endothelial rejection but in this case the split in Descemet's membrane was clearly seen. Hydrops has been reported previously in a corneal graft where the hydrops occurred in the host tissue or in the host-graft junction and extended into the corneal graft.
3,4 However, we believe that this is the first reported case, in which corneal hydrops has been found to occur purely in a corneal graft.
